Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

NMDA antagonists reported by Pfizer

May 17, 1996

Valproate effective in dementia patients

May 17, 1996

Increased platelet aggregation in AD patients

May 17, 1996

Sankyo claims allosteric muscarinic effectors for AD

May 17, 1996

GP-3269 on track for clinical testing

May 17, 1996

SB-204269 in phase I for epilepsy

May 17, 1996

Ketoconazole: Potential treatment for depression?

May 17, 1996

Scios to copromote venlafaxine with Wyeth-Ayerst

May 17, 1996

5-HT1D antagonists disclosed by SmithKline Beecham

May 17, 1996

Pfizer claims 5-HT1 agonists and antagonists for CNS disorders

May 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...